APA (7th ed.) Citation

G, S., M, K., & Y, K. (2025). ASO Author Reflections: Indication Criteria for Neoadjuvant Therapy for Resectable Pancreatic Ductal Adenocarcinoma. Annals of surgical oncology, 32(4), 2866. https://doi.org/10.1245/s10434-025-16980-z

Chicago Style (17th ed.) Citation

G, Shimane, Kitago M, and Kitagawa Y. "ASO Author Reflections: Indication Criteria for Neoadjuvant Therapy for Resectable Pancreatic Ductal Adenocarcinoma." Annals of Surgical Oncology 32, no. 4 (2025): 2866. https://doi.org/10.1245/s10434-025-16980-z.

MLA (9th ed.) Citation

G, Shimane, et al. "ASO Author Reflections: Indication Criteria for Neoadjuvant Therapy for Resectable Pancreatic Ductal Adenocarcinoma." Annals of Surgical Oncology, vol. 32, no. 4, 2025, p. 2866, https://doi.org/10.1245/s10434-025-16980-z.